Seres Therapeutics (MCRB) Misses Q4 EPS by 61c
Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.